KURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kura Oncology Inc (KURA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, options sentiment is not strongly bullish, and financial performance shows significant revenue decline. While analysts maintain positive ratings, the lack of recent news catalysts and insider selling trends suggest caution. Holding the stock or waiting for a clearer entry point is advisable.
The MACD is below 0 and negatively contracting, RSI is neutral at 45.032, and moving averages are converging. The stock is trading near its pivot point of 8.466 with support at 8.07 and resistance at 8.862. No strong bullish or bearish signals are evident.
Analysts maintain positive ratings with price targets significantly above the current price. Komzifti's market potential and sales growth in certain segments are seen as positives.
No recent news or Congress trading data to support a bullish sentiment.
In Q4 2025, revenue dropped significantly (-67.83% YoY) to $17.34M. Net income improved to -$80.99M (up 321.50% YoY), and EPS also improved to -0.92 (up 318.18% YoY). Gross margin remains high at 99.67% but slightly declined (-0.33% YoY).
Analysts maintain Buy or Outperform ratings with price targets ranging from $15 to $36. However, recent price target reductions reflect tempered expectations for near-term performance.
